Ovarian Cancer

MicroRNA and ovarian cancer
Ovarian cancer remains a leading cause of morbidity and mortality, with little change in survival rates over the past 30 years.

Ithaca, New York 14853
USA
Dietary glycaemic index, glycaemic load and endometrial and ovarian cancer risk: a systematic review
Long-term consumption of a high glycaemic index (GI) or glycaemic load (GL) diet may lead to chronic hyperinsulinaemia, which is a potential risk factor for cancer.
Mulhouse Building, Royal Victoria Hospital Site, Grosvenor Road, Belfast BT12 6BJ
Belfast, Ireland
UK
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ova
OBJECTIVE: Determine the safety and efficacy of cetuximab plus paclitaxel and carboplatin as initial treatment of stage III/IV ovarian cancer.

New York, NY 10065
USA
Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritone
OBJECTIVE: To determine the nature and degree of toxicity, response rate, quality of life (QOL), and progression-free interval in women with platinum-resistant refractory ovarian or peritoneal cancer receiving weekly topotecan and gemcitabine.

Seattle, Washington 19895
USA
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitum
PURPOSE: Sorafenib inhibits Raf kinase and vascular endothelial growth factor (VEGF) receptor.

Bethesda, MD
USA
Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a
PURPOSE: The management of recurrent ovarian cancer remains controversial.

Berlin, Germany
Germany
Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian
Histone deacetylase inhibitors (HDIs) as well as non-steroidal anti-inflammatory drugs including aspirin show promise as antineoplastic agents.

Jena, Germany
Germany
Fatigue in women receiving intraperitoneal chemotherapy for ovarian cancer: a review of contributing
Women diagnosed with stage III or IV ovarian cancer typically are treated with surgery followed by chemotherapy.

Chicago, IL
USA
Future directions in the management of epithelial ovarian cancer
Epithelial ovarian cancer can be a difficult malignancy to manage, partially owing to its heterogenous biology.
Hammersmith Campus, Du Cane Road, London, W12 0NN
London, UK
UK
[Intraperitoneal chemotherapy for ovarian cancer]
Standard therapy for advanced ovary cancer is T-C chemotherapy (paclitaxel, carboplatin) after initial cytoreductive surgery.

Hiroshima, Japan
Japan